Loading data for CCCC — first visit, this takes a few seconds.
C4 Therapeutics, Inc. (CCCC)
NasdaqGS: CCCC
· 即時價格 · USD
3.51
+0.11 (3.24%)
收盤價： Sep 11, 2026, 3:59 PM
3.50
-0.28%
盤後: 7:30 PM
股價、關鍵數字和最新消息，都在這一頁。
C4 Therapeutics, Inc.（CCCC）股價、分析與資料
3.24% (1D)
| 買價 | 2.5 |
| 市值 | 432M |
| 營收 (ttm) | 35M |
| 淨利（ttm） | -101M |
| 2.94 | |
| -0.91 | |
| n/a | |
| -3.52 | |
| P/B (ttm) | 1.74 |
| P/S (ttm) | 12.32 |
| 財報日期 | Nov 5, 2026 |
| 賣價 | 4.33 |
| 成交量 | 1,459,783 |
| 20 日平均成交量 | 2,986,804 |
| 開盤價 | 3.46 |
| 前收盤價 | 3.40 |
| 當日區間 | 3.35 - 3.52 |
| 52 週範圍 | 1.69 - 5.17 |
| 分析師 | n/a |
| 目標價 | n/a |
| 股利 | n/a |
| 除息日 | n/a |
關於 CCCC
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, ...
完整的公司簡介財報驚奇
C4 Therapeutics 已於 Aug 11, 2026 公布季度財報：
- 營收為 $6.64M 低於預期 $0, 年增 2.75% 成長.
- 每股盈餘為 -0.18 超出預期 0.05, 年增 51.35% 成長.
第 1 頁，共 2 頁